logo
Share SHARE
FONT-SIZE Plus   Neg

Boehringer Ingelheim, Eli Lilly Submit NDA For Empagliflozin - Quick Facts

Boehringer Ingelheim and Eli Lilly and Company (LLY: Quote) announced that a New Drug Application for the investigational sodium glucose co-transporter-2 inhibitor empagliflozin was recently submitted to the FDA for the treatment of type 2 diabetes mellitus in adults.

Empagliflozin is a member of the SGLT2 inhibitor class of drugs being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption in the kidney.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Uber Technologies Inc., the company behind the famous ride-sharing app, is expanding its pilot food delivery service program, UberEATS, to New York City and Chicago. Uber's new pilot program allows customers to order a meal that will be delivered to them within ten minutes. There is a $3 delivery... Standard Chartered said it is still reviewing whether to shift its headquarters out of London, at a time when banks in Britain face higher levy and regulatory costs. Tyson Foods Inc. (TSN) Tuesday said it plans to eliminate the use of human antibiotics from its chicken production, as the meat producing giant joins other peers who have taken similar steps in the wake of health concerns. Tyson Foods said it is striving to eliminate the use of antibiotics from its...
comments powered by Disqus
RELATED NEWS
Trade LLY now with 
Follow RTT